List view / Grid view
21 April 2016 | By Victoria White, Digital Content Producer
Novo Nordisk has announced that it plans to invest more than 100 million euros in production facilities at its site in Chartres, France...
21 April 2016 | By Victoria White, Digital Content Producer
Results from a Phase III study show Novartis’ Afinitor (everolimus), when used as an adjunctive therapy, significantly reduced treatment-resistant seizures...
20 April 2016 | By Victoria White, Digital Content Producer
Pfizer has announced positive top-line results from the Phase III PALOMA-2 trial for Ibrance (palbociclib) in breast cancer...
20 April 2016 | By CPhI
CPhI Istanbul 2016, organised by UBM EMEA, returns for the third consecutive year to Turkey, co-located with InnoPack, ICSE and P-MEC...
20 April 2016 | By Victoria White, Digital Content Producer
Data from a Phase I study of a preventive Ebola vaccine regimen suggest that the regimen was well-tolerated by healthy volunteers and immunogenic...
19 April 2016 | By Victoria White, Digital Content Producer
The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, according to GlobalData...
19 April 2016 | By Mandy Parrett, Editorial Assistant
Sanofi has announced plans to invest €300 million to expand its manufacturing and commercial capabilities at its site in Geel, Belgium.
Kyowa Hakko Kirin (KHK), the company that acquired ProStraken in 2011, has decided that its western pharmaceutical subsidiaries are to adopt the Kyowa Kirin name...
19 April 2016 | By Victoria White, Digital Content Producer
Boehringer Ingelheim and Lilly have announced plans to conduct two trials investigating Jardiance for the treatment of people with chronic heart failure...
18 April 2016 | By Victoria White, Digital Content Producer
Biogen has unveiled new Tecfidera research that reinforces its sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis patients...
18 April 2016 | By Victoria White, Digital Content Producer
A Opdivo and Yervoy combination regimen demonstrated a two-year OS rate of 69% compared to 53% for Yervoy alone in BRAF wild-type advanced melanoma...
18 April 2016 | By Victoria White, Digital Content Producer
With eight weeks of treatment, 97-98 percent of GT1-3 HCV infected patients without cirrhosis treated with ABT-493 and ABT-530 achieved sustained SVR12...
18 April 2016 | By Victoria White, Digital Content Producer
NICE has recommended Translarna (ataluren) for treating children aged 5 and over with Duchenne muscular dystrophy caused by a nonsense mutation...
15 April 2016 | By Victoria White, Digital Content Producer
Studies 108 and 110 were 48-week clinical trials evaluating TAF among 1,298 treatment-naïve and treatment-experienced patients with chronic HBV infection...
15 April 2016 | By Victoria White, Digital Content Producer
AstraZeneca has reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC).
